Our roadmaps ensure you have the evidence you need, in the right format, for the right audience, at the right time. Our roadmap services enable global development teams to understand the evolving market access and health economics and outcomes research (HEOR) landscape.
Through the development of a product-specific roadmap we highlight strategic requirements and define tactical implementation activities. Our roadmaps outline the challenges that need to be addressed at global and country-specific levels. Our roadmaps define the detailed activities that will be required to meet the demands of payers and other key stakeholders, including patients and clinicians. We use our existing local and global knowledge, supplemented with new research, to comprehensively understand the evidence generation activities that will be required to meet the needs of each market of interest. We map these out across the drug development timeline to ensure that robust and relevant evidence is available for communication in a timely manner.
Our roadmaps identify:
Our roadmaps are critical for informing trial design, including choice of comparators, target populations, sub-groups, and relevant outcomes, and are most effective when devised during early drug development. Our extensive experience in HTA and value proposition development ensures that our roadmaps address the needs of all key decision-makers across the lifecycle of the brand.
We are part of Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd.
DRG offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 offices in North America, Europe and Asia.Our Company